Dupont Capital Management Corp lessened its holdings in shares of Steris PLC (NYSE:STE) by 7.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,200 shares of the medical equipment provider’s stock after selling 4,156 shares during the period. Dupont Capital Management Corp owned about 0.06% of Steris worth $5,628,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Steris by 1.8% during the second quarter. BlackRock Inc. now owns 7,608,114 shares of the medical equipment provider’s stock valued at $798,929,000 after buying an additional 131,142 shares during the period. WCM Investment Management CA boosted its position in shares of Steris by 122.3% during the third quarter. WCM Investment Management CA now owns 2,278,403 shares of the medical equipment provider’s stock valued at $260,650,000 after buying an additional 1,253,653 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Steris by 4.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,269,194 shares of the medical equipment provider’s stock valued at $259,595,000 after buying an additional 103,392 shares during the period. Bessemer Group Inc. boosted its position in shares of Steris by 1.2% during the second quarter. Bessemer Group Inc. now owns 1,350,926 shares of the medical equipment provider’s stock valued at $141,863,000 after buying an additional 16,460 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Steris by 6.8% during the second quarter. Wells Fargo & Company MN now owns 1,289,590 shares of the medical equipment provider’s stock valued at $135,421,000 after buying an additional 81,588 shares during the period. Institutional investors and hedge funds own 89.52% of the company’s stock.
Steris stock opened at $120.35 on Friday. The company has a quick ratio of 2.02, a current ratio of 2.63 and a debt-to-equity ratio of 0.41. Steris PLC has a fifty-two week low of $82.88 and a fifty-two week high of $121.67. The company has a market cap of $9.93 billion, a PE ratio of 29.00 and a beta of 1.03.
Steris (NYSE:STE) last posted its quarterly earnings results on Tuesday, November 6th. The medical equipment provider reported $1.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.02. Steris had a net margin of 11.72% and a return on equity of 12.15%. The firm had revenue of $679.00 million during the quarter, compared to the consensus estimate of $659.14 million. During the same quarter in the previous year, the firm posted $0.94 earnings per share. The company’s revenue was up 7.1% on a year-over-year basis. On average, sell-side analysts predict that Steris PLC will post 4.71 EPS for the current year.
In other news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of Steris stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $120.50, for a total transaction of $1,205,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Karen L. Burton sold 1,300 shares of Steris stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $114.39, for a total transaction of $148,707.00. The disclosure for this sale can be found here. Insiders have sold 45,800 shares of company stock valued at $5,464,727 in the last ninety days. Insiders own 2.38% of the company’s stock.
Several brokerages have issued reports on STE. Zacks Investment Research upgraded Steris from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. JMP Securities boosted their target price on Steris from $113.00 to $125.00 and gave the company a “market outperform” rating in a research report on Thursday, August 9th. KeyCorp boosted their target price on Steris from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, August 9th. Finally, Stephens restated a “buy” rating and set a $125.00 target price on shares of Steris in a research report on Thursday, August 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Steris currently has an average rating of “Buy” and a consensus target price of $115.00.
ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/11/10/steris-plc-ste-holdings-lessened-by-dupont-capital-management-corp.html.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Featured Story: Index Funds
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.